Handelsbanken Fonder AB Acquires 44,894 Shares of Globus Medical, Inc. $GMED

Handelsbanken Fonder AB lifted its holdings in Globus Medical, Inc. (NYSE:GMED) by 102.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,791 shares of the medical device company’s stock after purchasing an additional 44,894 shares during the quarter. Handelsbanken Fonder AB’s holdings in Globus Medical were worth $7,752,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Radnor Capital Management LLC lifted its position in shares of Globus Medical by 3.0% in the fourth quarter. Radnor Capital Management LLC now owns 34,140 shares of the medical device company’s stock worth $2,981,000 after purchasing an additional 1,004 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Globus Medical by 0.8% in the fourth quarter. HighTower Advisors LLC now owns 40,788 shares of the medical device company’s stock worth $3,561,000 after purchasing an additional 322 shares in the last quarter. North Dakota State Investment Board bought a new stake in shares of Globus Medical in the fourth quarter worth $343,000. ANTIPODES PARTNERS Ltd lifted its position in shares of Globus Medical by 1.8% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 906,833 shares of the medical device company’s stock worth $79,182,000 after purchasing an additional 15,790 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Globus Medical by 71,618.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock worth $62,555,000 after purchasing an additional 715,470 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Activity at Globus Medical

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 18.38% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on GMED. Wells Fargo & Company cut their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Barclays boosted their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Trading Up 0.3%

Shares of GMED opened at $84.84 on Friday. The company has a market cap of $11.52 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 1.74 and a beta of 1.00. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company’s fifty day simple moving average is $87.26 and its 200 day simple moving average is $87.80.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.